Personalized Ophthalmology Therapies Market Report 2025

The personalized ophthalmology therapies market size has grown rapidly in recent years. It will grow from $2.82 billion in 2024 to $3.23 billion in 2025 at a compound annual growth rate (CAGR) of 14.4%. Growth in the historic period was driven by rising rates of diabetes, government initiatives, an aging population, growing demand for precision medicine in eye care, and increasing prevalence of ophthalmic diseases.

The personalized ophthalmology therapies market size is expected to see rapid growth in the next few years. It will grow to $5.46 billion in 2029 at a compound annual growth rate (CAGR) of 14%. Growth in the forecast period is expected to be supported by greater accessibility of genetic testing and molecular diagnostics, increasing cases of age-related macular degeneration, rising awareness of personalized medicine, higher healthcare expenditure, and growing investment in ophthalmic research. Key trends anticipated for the forecast period include strategic collaborations between biotechnology firms, research institutes, and healthcare providers, deployment of artificial intelligence and machine learning in ophthalmology, integration of genomics with digital health technologies, rapid advancements in genetic and cellular therapies, and adoption of advanced technological solutions.

The growing prevalence of chronic vision disorders is expected to drive the expansion of the personalized ophthalmology therapies market. Chronic vision disorders are long-term eye conditions that progressively impair vision and often require continuous management. The rise in these disorders is closely linked to the increasing global incidence of diabetes, which can lead to complications such as diabetic retinopathy - a condition that gradually damages the retina over time. Personalized ophthalmology therapies are designed to address such chronic disorders by tailoring treatment plans based on an individual's genetic and molecular profile. This personalized approach enhances treatment effectiveness and helps slow disease progression. For example, in May 2024, the Centers for Disease Control and Prevention, a government health agency in the United States, projected that if effective interventions are not implemented, the number of diabetic retinopathy cases will increase by 72 percent, while cataract cases are expected to grow by 87 percent by the year 2050. These trends underscore the growing demand for individualized treatments in ophthalmology.

Leading companies in the personalized ophthalmology therapies market are advancing the development of single-dose intravitreal gene therapies to reduce the frequency of treatments and associated complications. These therapies involve a one-time injection into the vitreous cavity of the eye to deliver genetic material that targets the underlying cause of the disorder, providing long-lasting therapeutic effects. For instance, in July 2025, Sanofi, a pharmaceutical and healthcare company based in France, received fast track designation from the United States Food and Drug Administration for SAR446597, a single-dose intravitreal gene therapy aimed at treating geographic atrophy caused by age-related macular degeneration. This therapy delivers genetic material that encodes two antibody fragments which inhibit components of the classical and alternative complement pathways, specifically targeting C1s and factor Bb. By suppressing these pathways, the treatment aims to slow disease progression in the retina and reduce the need for repeated injections. The fast track designation is intended to accelerate the development and regulatory review process for therapies that address serious medical conditions with limited treatment options.

In June 2022, Novartis, a pharmaceutical company headquartered in Switzerland, acquired Kedalion Therapeutics for an undisclosed amount. This acquisition enables Novartis to expand its capabilities in precision ocular drug delivery technologies. Kedalion Therapeutics has developed innovative approaches to enhance the administration and effectiveness of eye treatments while improving patient comfort. The acquisition aligns with Novartis' strategic focus on delivering patient-centric, personalized solutions for a broad range of eye conditions and reinforces its position in the ophthalmology market.

Major players in the personalized ophthalmology therapies market are Roche Holding AG, Novartis AG, Regeneron Pharmaceuticals Inc., Alcon Inc., Genentech Inc., Bausch + Lomb Corporation, Johnson & Johnson Vision Care Inc., Carl Zeiss Meditec AG, Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Senju Pharmaceutical Co. Ltd., MeiraGTx Ltd., Beacon Therapeutics, Clearside Biomedical Inc., Adverum Biotechnologies Inc., Ocugen Inc., GenSight Biologics, Nanoscope Therapeutics Inc., 4D Molecular Therapeutics Inc., Coave Therapeutics.

North America was the largest region in the personalized ophthalmology therapies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in personalized ophthalmology therapies report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the personalized ophthalmology therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Personalized ophthalmology therapies are customized treatment approaches for eye diseases and vision disorders that are tailored to an individual patient’s genetic profile, molecular characteristics, lifestyle, and clinical condition. These therapies utilize advances in genomics, biomarker analysis, imaging, and precision medicine to optimize drug selection, dosage, or surgical interventions for conditions such as age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, and inherited retinal diseases.

The primary types of personalized ophthalmology therapies include gene therapy, cell therapy, pharmacogenomics, targeted drug delivery, and others. Gene therapy involves introducing or modifying genetic material within a patient’s cells to treat eye diseases caused by genetic mutations. These therapies are applied for various indications including AMD, diabetic retinopathy, glaucoma, and retinitis pigmentosa, and are used by hospitals, specialty clinics, research institutes, and other healthcare organizations.

The personalized ophthalmology therapies market research report is one of a series of new reports that provides personalized ophthalmology therapies market statistics, including personalized ophthalmology therapies industry global market size, regional shares, competitors with a personalized ophthalmology therapies market share, detailed personalized ophthalmology therapies market segments, market trends and opportunities, and any further data you may need to thrive in the personalized ophthalmology therapies industry. This personalized ophthalmology therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The personalized ophthalmology therapies market includes revenues earned by entities by providing services such as molecular profiling, biomarker identification, patient data integration services, and disease risk assessment. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.